Prescription drug · NDA
Lifyorli (relacorilant) NDC 76346-425
Kit · Oral · Corcept Therapeutics Incorporated
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 76346-425-01 | 76346042501 | 1 BLISTER PACK in 1 CARTON (76346-425-01) / 1 KIT in 1 BLISTER PACK (76346-425-11) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)Marketed from Mar 25, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lifyorli
- Generic name (nonproprietary)
- relacorilant
- Dosage form
- Kit
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220641
- Marketing start
- Listing expires
- Identifiers
- Product ID 76346-425_41bf3142-d0f6-4f0c-b6da-5abe8ad3db43SPL ID 41bf3142-d0f6-4f0c-b6da-5abe8ad3db43SPL set ID 6fcebfb5-19d6-4f63-b852-999d68a13729RxCUI 2739542, 2739548, 2739550, 2739552, 2739553, 2739554, 2739555, 2739556, 2739557, 2739558, 2739559, 2739560, 2739561, 2739562, 2739563, 2739564
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N476346042501followed by a unit qualifier and the quantityPackage 76346-0425-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )] . LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. ( 1 , 14 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 220641
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.